echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Aduhelm controversy has not yet ended the Bojian Tecfidera generic drug patent case has fallen again

    The Aduhelm controversy has not yet ended the Bojian Tecfidera generic drug patent case has fallen again

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    Despite Bojian’s best efforts, Tecfidera generic drugs seem to continue to be sold on the market


    According to court documents filed on Tuesday, the U.


    This case originated from a long-standing patent dispute between Bojian and Viatris, whose predecessor was Mylan


    At that time, Bojian filed an appeal


    According to Tuesday’s ruling, Bo Jianfang can still apply for a retrial and may appeal to the Supreme Court


    Abrahams added that due to the bad news from Tecfidera and Bojian’s struggling in several other business areas, the company’s stock price may be “close to the bottom”


    However, the fact is that the drug has continued to face safety disputes and payment barriers after it was approved by the US FDA


    However, the company did not completely give up its efforts in the multiple sclerosis market.


    Reference source: Biogen takes another blow as appeal for Tecfidera patent revival falls short

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.